The many faces of macrophage activation

It used to be easy. In the old days ( 8 years ago), activated macrophages were simply defined as cells that secreted inflammatory mediators and killed intracellular pathogens. Things are becoming progressively more complicated in the world of leukocyte biology. Activated macrophages may be a more heterogenous group of cells than originally appreciated, with different physiologies and performing distinct immunological functions. The first hint of this heterogeneity came with the characterization of the “alternatively activated macrophage” [1]. The exposure of macrophages to interleukin (IL)-4 or glucocorticoids induced a population of cells that up-regulated certain phagocytic receptors but failed to produce nitrogen radicals [2] and as a result, were relatively poor at killing intracellular pathogens. Recent studies have shown that these alternatively activated cells produce several components involved in the synthesis of the extracellular matrix (ECM) [3], suggesting their primary role may be involved in tissue repair rather than microbial killing. It turns out that the name alternatively activated macrophage may be unfortunate for a few reasons. First, although these cells express some markers of activation, they have not been exposed to the classical, activating stimuli, interferon(IFN) and lipopolysaccharide (LPS). Second, and more importantly, the name implies that this is the only other way to activate a macrophage. Recent studies suggest that this may not be the case. Exposure of macrophages to classical activating signals in the presence of immunoglobulin G (IgG) immune complexes induced the production of a cell type that was fundamentally different from the classically activated macrophage. These cells generated large amounts of IL-10 and as a result, were potent inhibitors of acute inflammatory responses to bacterial endotoxin [4]. These activated macrophages have been called type 2-activated macrophages [5] because of their ability to induce T helper cell type 2 (Th2) responses that were predominated by IL-4 [6], leading to IgG class-switching by B cells. Thus, at this time, there appears to be at least three different populations of activated macrophages with three distinct biological functions. The first and most well described is the classically activated macrophage whose role is as an effector cell in Th1 cellular immune responses. The second type of cell, the alternatively activated macrophage, appears to be involved in immunosuppression and tissue repair. The most recent addition to this list is the type 2-activated macrophage, which is anti-inflammatory and preferentially induces Th2-type humoral-immune responses to antigen. Together, these three populations of cells may form their own regulatory network to prevent a well-intentioned immune response from progressing to immunopathology. THE CLASSICALLY ACTIVATED MACROPHAGE

[1]  J. Ihle,et al.  Cutting Edge: Stat6-Dependent Substrate Depletion Regulates Nitric Oxide Production1 , 2001, The Journal of Immunology.

[2]  B. Antus,et al.  Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. , 2000, Cellular immunology.

[3]  J. Hibbs Infection and nitric oxide. , 2002, The Journal of infectious diseases.

[4]  A. Ho,et al.  Interleukin-10 and its receptor. , 1994, Therapeutic immunology.

[5]  S. Kinare,et al.  Association of lung carcinoma and tuberculosis. , 1991, Journal of postgraduate medicine.

[6]  P. De Baetselier,et al.  Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages , 2002, Journal of leukocyte biology.

[7]  S. Goerdt,et al.  Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro , 1997, Immunology.

[8]  S. Gordon,et al.  Alterations of surface properties by macrophage activation: expression of receptors for Fc and mannose-terminal glycoproteins and differentiation antigens. , 1984, Contemporary topics in immunobiology.

[9]  J. Gerber,et al.  Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. , 2001, Journal of immunology.

[10]  C. Nathan Mechanisms and modulation of macrophage activation. , 1991, Behring Institute Mitteilungen.

[11]  S. Reed TGF-beta in infections and infectious diseases. , 1999, Microbes and infection.

[12]  D. Mosser,et al.  Treatment of murine macrophages with interferon‐γ inhibits their ability to bind leishmania promastigotes , 1992, Journal of leukocyte biology.

[13]  S. Goerdt,et al.  Alternatively Activated Macrophages Differentially Express Fibronectin and Its Splice Variants and the Extracellular Matrix Protein βIG‐H3 , 2001, Scandinavian journal of immunology.

[14]  L. Ting,et al.  Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. , 1999, Journal of immunology.

[15]  Ho As,et al.  Interleukin-10 and its receptor. , 1994 .

[16]  E. Pearce,et al.  Differential Regulation of Nitric Oxide Synthase-2 and Arginase-1 by Type 1/Type 2 Cytokines In Vivo: Granulomatous Pathology Is Shaped by the Pattern of l-Arginine Metabolism1 , 2001, The Journal of Immunology.

[17]  F. Sutterwala,et al.  Reversal of Proinflammatory Responses by Ligating the Macrophage Fcγ Receptor Type I , 1998, The Journal of experimental medicine.

[18]  S Gordon,et al.  Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation , 1992, The Journal of experimental medicine.

[19]  N. Reiner,et al.  Exploitation of host cell signaling machinery: activation of macrophage phosphotyrosine phosphatases as a novel mechanism of molecular microbial pathogenesis , 2000, Journal of leukocyte biology.

[20]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[21]  David M. Mosser,et al.  Cutting Edge: Biasing Immune Responses by Directing Antigen to Macrophage Fcγ Receptors1 , 2002, The Journal of Immunology.

[22]  J. Gerber,et al.  Reversing Lipopolysaccharide Toxicity by Ligating the Macrophage Fcγ Receptors1 , 2001, The Journal of Immunology.

[23]  D. Mosser,et al.  Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. , 2002, Journal of immunology.

[24]  S. Goerdt,et al.  Other functions, other genes: alternative activation of antigen-presenting cells. , 1999, Immunity.

[25]  P. H. Correll,et al.  Activation of the Stem Cell-Derived Tyrosine Kinase/RON Receptor Tyrosine Kinase by Macrophage-Stimulating Protein Results in the Induction of Arginase Activity in Murine Peritoneal Macrophages1 , 2002, The Journal of Immunology.

[26]  D. Mosser,et al.  A novel phenotype for an activated macrophage: the type 2 activated macrophage , 2002, Journal of leukocyte biology.

[27]  F. Sutterwala,et al.  Selective Suppression of Interleukin-12 Induction after Macrophage Receptor Ligation , 1997, The Journal of experimental medicine.

[28]  T. Gingeras,et al.  Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. , 2001, The Journal of experimental medicine.

[29]  S. Goerdt,et al.  Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. , 1998, Journal of immunology.

[30]  M. Modolell,et al.  Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse bone marrow‐derived macrophages by TH 1 and TH 2 cytokines , 1995, European journal of immunology.

[31]  P. Gros,et al.  Genetic susceptibility to intracellular infections: Nramp1, macrophage function and divalent cations transport. , 2000, Current opinion in microbiology.

[32]  C. Nathan,et al.  Nitric oxide and macrophage function. , 1997, Annual review of immunology.

[33]  Kinare Sg,et al.  Association of lung carcinoma and tuberculosis. , 1991 .

[34]  R. Flavell The relationship of inflammation and initiation of autoimmune disease: role of TNF super family members. , 2002, Current topics in microbiology and immunology.

[35]  T. Gingeras,et al.  Reprogramming of the Macrophage Transcriptome in Response to Interferon-γ and Mycobacterium tuberculosis , 2001, The Journal of experimental medicine.

[36]  V. Fadok,et al.  Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. , 2002, The Journal of clinical investigation.

[37]  E. Borden,et al.  Interferon‐lnduced Indoleamine 2,3‐Dioxygenase Activity in Human Mononuclear Phagocytes , 1989, Journal of leukocyte biology.

[38]  Constantin E. Orfanos,et al.  Alternative versus Classical Activation of Macrophages , 2000, Pathobiology.

[39]  S. Reed TGF-β in infections and infectious diseases , 1999 .